tradingkey.logo

Stoke Therapeutics Expects To Complete Enrollment Of 150 Patients In Q2 2026, With A Phase 3 Data Readout In Mid-2027 for Zorevunersen

ReutersJan 11, 2026 7:03 PM

- Stoke Therapeutics Inc STOK.O:

  • STOKE THERAPEUTICS ANNOUNCES UPDATES TO TIMELINES FOR THE COMPLETION OF ENROLLMENT AND A PHASE 3 DATA READOUT FROM THE EMPEROR STUDY OF ZOREVUNERSEN FOR THE TREATMENT OF DRAVET SYNDROME

  • STOKE THERAPEUTICS INC: EXPECTS TO COMPLETE ENROLLMENT OF 150 PATIENTS IN Q2 2026, WITH A PHASE 3 DATA READOUT IN MID-2027

  • STOKE THERAPEUTICS INC - CONTINUES TO EXPLORE POTENTIAL FOR EXPEDITED DEVELOPMENT, REGISTRATION AND DELIVERY OF ZOREVUNERSEN TO PATIENTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI